116
Participants
Start Date
October 31, 2007
Primary Completion Date
September 30, 2011
Study Completion Date
December 31, 2013
bevacizumab
15 mg/m2 given through a vein for every 3 weeks
carboplatin
AUC = 6 given through a vein on day 1 of each cycle.
erlotinib hydrochloride
150 mg taken by mouth daily
paclitaxel
200 mg/m2 given through a vein on day 1 of each cycle.
gene expression analysis
Blood and tissue collection.
protein expression analysis
Blood and tissue collection.
proteomic profiling
Blood and tissue collection.
laboratory biomarker analysis
Blood and tissue collection.
Emory University, Atlanta
Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville
Vanderbilt-Ingram Cancer Center at Franklin, Nashville
University of Florida Shands Cancer Center, Gainesville
University of Michigan Comprehensive Cancer Center, Ann Arbor
Vanderbilt-Ingram Cancer Center, Nashville
M. D. Anderson Cancer Center at University of Texas, Houston
National Cancer Institute (NCI)
NIH
Vanderbilt-Ingram Cancer Center
OTHER